Abstract

A multi-target small molecule modulator is advantageous for treating complicated diseases such as cancers. However, the strategy and application for discovering a multi-target modulator have been less reported. This study presents the dual inhibitors for kinase and carbonic anhydrase (CA) predicted by machine learning (ML) classifiers, and validated by biochemical and biophysical experiments. ML trained by CA I and CA II inhibitor molecular fingerprints predicted candidates from the protein-specific bioactive molecules approved or under clinical trials. For experimental tests, three sulfonamide-containing kinase inhibitors, 5932, 5946, and 6046, were chosen. The enzyme assays with CA I, CA II, CA IX, and CA XII have allowed the quantitative comparison in the molecules’ inhibitory activities. While 6046 inhibited weakly, 5932 and 5946 exhibited potent inhibitions with 100 nM to 1 μM inhibitory constants. The ML screening was extended for finding CAs inhibitors of all known kinase inhibitors. It found XMU-MP-1 as another potent CA inhibitor with an approximate 30 nM inhibitory constant for CA I, CA II, and CA IX. Differential scanning fluorimetry confirmed the direct interaction between CAs and small molecules. Cheminformatics studies, including docking simulation, suggest that each molecule possesses two separate functional moieties: one for interaction with kinases and the other with CAs.

Highlights

  • A molecule targeting a single disease-related protein often causes insufficient efficacy, even potent from the viewpoint of target engagement

  • We digitized the SMILES of each chemical with three fingerprints [29,30], extended-connectivity fingerprint

  • Imperfectness in the algorithm and the training dataset brings about vast false positives in computer-assisted screens [55,56], necessitating experimental confirmation

Read more

Summary

Introduction

A molecule targeting a single disease-related protein often causes insufficient efficacy, even potent from the viewpoint of target engagement. Therapeutic strategies for treating cancer, neurodegenerative, cardiovascular, and infectious diseases often necessitate multiple target simultaneous modulation due to their complicated origins [1,2,3]. Targeting numerous targets may increase side effects. There is an increasing interest in developing therapeutics that selectively manipulate multiple desired pathways at once [4]. The second approach is a single molecule that can modulate several targets. Multi-target-directing molecules are advantageous because of the fewer side effects and toxicities [5,6]. Instead, finding and designing a molecule with multiple functions is not straightforward, necessitating an effective strategy [4,7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call